Atlas Trials

MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents

Clinical trial NCT03217097 · COMPLETED

Trial details

NCT number
NCT03217097
Sponsor
Hospices Civils de Lyon
Status
COMPLETED
Phase
Not Applicable
Study type
INTERVENTIONAL
Neuroendocrine Tumors
Start date
2018-10-16
Primary completion
2022-01-31
Enrollment
116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.